Lamassu BioTech

Lamassu Biotech is a private, clinical stage biopharmaceutical company that uses innovative processes to speed up the development of transformational treatments for humans and animals. Lamassu’s patient-centric approach to research and drug development focuses on making advancements that address unmet needs with novel and targeted strategies, ensuring greater efficiency and shorter approval timeframes.

The company is pioneering a genetically targeted novel therapeutic to combat locally advanced metastatic p53 wild-type tumors, using SA53 (Selective Activator of p53) to targets the MDM2 protein, a key regulator of the tumor suppressor p53 gene. SA53 has earned investigational new drug application (IND) approval from the Food and Drug Administration (FDA) and is currently undergoing Phase 1/2a clinical trials at Cleveland Clinic.

Lamassu is also advancing a novel small molecule therapy for acute pancreatitis, RABI-767, which was developed at by leading scientists Mayo Clinic. The drug has shown profound efficacy to completely mitigate mortality and morbidity and is currently undergoing Phase II clinical trial in partnership with Arrivo BioVentures.

Lamassu Pets, the veterinary division of Lamassu Biotech, is collaborating with The Ohio State University to advance a National Institutes of Health (NIH)-funded clinical trial of canine RABI-767, a novel therapeutic targeting acute pancreatitis in dogs. Canine acute pancreatitis (CAP) is a life-threatening condition that currently has no effective treatments in veterinary medicine.